INS and type 1 diabetes mellitus: Clinical trials using Treg have shown improved but not as promising results as expected, with only a few clinical studies showing that higher levels of Tregs and IL2 appear to improve endogenous insulin secretion in T1D, and the exploration of insulinogenic-specific Tregs in the immune response of patients with T1DM needs to continue in-depth (34–37).